I think you are right about ESMO data...
I originally thought abstract release this Thursday would have additional data, but after second look, the data presented at ASCO used April 17th as cut-off, same day as deadline for ESMO abstracts (coincidence?). So I think we have to wait until Saturday the 28th, 5:27AM EST to get the good news.
Last year data cut-off for ESMO was just one week prior to meeting so this would mean 5 additional months since ASCO data, with 2-3 months of enrollment in cohorts #1-4 (assumed early July). Patients who received the 180mg dose in Phase 1 convert to Phase 2, so potentially 12-18 months on study. In my opinion duration of response is the final piece needed to be confirm best-in-class.
